On December 8th, 2025, Ascentage Pharma Group International shared significant updates at the 67th American Society of Hematology Annual Meeting in Orlando, Florida. The company, listed on NASDAQ under AAPG and on HKEX as 6855, presented long-term findings from a four-year follow-up on a Phase II study of Olverembatinib. This study focused on patients with tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic-phase chronic myeloid leukemia (CML-CP). The data displayed during a poster presentation underscored Olverembatinib's enduring positive effects and safety profile. The previous results were first revealed during an oral presentation at ASH 2023. Ascentage Pharma Group International is a global biopharmaceutical firm dedicated to developing innovative therapies for unmet medical needs in the realm of cancer treatment.
